1446236-46-9

Upstream product

• 29241-62-1 5-bromo-6-chloronicotinic acid 
• 367-27-1 2,4-difluorophenol 
• 1446236-44-7 5-bromo-6-(2,4-difluorophenoxy)nicotinic acid 
• 1446236-45-8 (5-bromo-6-(2,4-difluorophenoxy)pyridin-3-yl)methanol 
• 78686-77-8 5-bromo-6-chloro-3-pyridinecarboxylic acid methyl ester 

Downstream Products

• 1446235-45-5 4-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]pyridin-3-yl}-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 
• 1446236-48-1 3-bromo-2-(2,4-difluorophenoxy)-5-(methylsulfonylmethyl)pyridine 
• 1446236-47-0 3-bromo-2-(2,4-difluorophenoxy)-5-(methylthiomethyl)pyridine 

Relevant academic research and scientific papers

Discovery of 8-Methyl-pyrrolo[1,2-a]pyrazin-1(2 H)-one Derivatives as Highly Potent and Selective Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitors

The bromodomain and extra-terminal (BET) family proteins have recently emerged as promising drug targets for cancer therapy. In this study, identification of an 8-methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one fragment (47) as a new binder to the BET bromodomains

Bromine structural domain inhibitor compound and application thereof

The invention relates to a bromine structural domain inhibitor and provides a compound shown in a general formula I, pharmaceutical salt, an enantiomer, a diastereoisomer, an atropisomer, racemate, apolymorphic substance and solvate of the compound or an isotope labelled compound (including a deuterium substituted compound), a preparation method of the compound, pharmaceutical composition containing the compound and an application of the above components in pharmaceuticals.

BROMODOMAIN INHIBITORS

The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

DIHYDRO-PYRROLOPYRIDINONE INHIBITORS

The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, and R5 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).